School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.
School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China
BMJ Open. 2024 Apr 2;14(4):e079354. doi: 10.1136/bmjopen-2023-079354.
Specific treatment for diabetic peripheral neuropathy (DPN) is still lacking, and acupuncture may relieve the symptoms. We intend to investigate the efficacy and safety of electro-acupuncture (EA) in alleviating symptoms associated with DPN in diabetes.
This multicentre, three-armed, participant- and assessor-blind, randomised, sham-controlled trial will recruit 240 eligible participants from four hospitals in China and will randomly assign (1:1:1) them to EA, sham acupuncture (SA) or usual care (UC) group. Participants in the EA and SA groups willl receive either 24-session EA or SA treatment over 8 weeks, followed by an 8-week follow-up period, while participants in the UC group will be followed up for 16 weeks. The primary outcome of this trial is the change in DPN symptoms from baseline to week 8, as rated by using the Total Symptom Score. The scale assesses four symptoms: pain, burning, paraesthesia and numbness, by evaluating the frequency and severity of each. All results will be analysed with the intention-to-treat population.
The protocol has been approved by the Ethics Committee of the Beijing University of Chinese Medicine (Identifier: 2022BZYLL0509). Every participant will be informed of detailed information about the study before signing informed consent. The results of this trial will be published in a peer-reviewed journal.
ChiCTR2200061408.
目前针对糖尿病周围神经病变(DPN)的特定治疗方法仍然缺乏,而针灸可能有助于缓解相关症状。本研究旨在探讨电针对缓解糖尿病周围神经病变相关症状的疗效和安全性。
本项多中心、三臂、参与者和评估者双盲、随机、假对照试验将从中国的 4 家医院招募 240 名符合条件的参与者,并将其随机分为电针(EA)、假针刺(SA)或常规治疗(UC)组(1:1:1)。EA 和 SA 组的参与者将接受 24 次 EA 或 SA 治疗,共 8 周,随后进行 8 周的随访期,而 UC 组的参与者将随访 16 周。本试验的主要结局是通过总症状评分评估的 DPN 症状从基线到第 8 周的变化。该量表通过评估每种症状的频率和严重程度来评估四个症状:疼痛、烧灼感、感觉异常和麻木。所有结果均将根据意向治疗人群进行分析。
该方案已获得北京中医药大学伦理委员会的批准(标识符:2022BZYLL0509)。在签署知情同意书之前,每位参与者都将被告知有关研究的详细信息。本试验的结果将发表在同行评议的期刊上。
ChiCTR2200061408。